RxDoctor Payments DataLook up a doctor →

Keith Chu, MD

Cardiovascular Disease · Manassas, VANPI 1871537365

Payments from drug & device makers

$464,222in general payments, 2019–2025

Across 888 payments — averaging $522.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$286K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$146K
  • Amarin Pharma, Inc.$20K
  • Boehringer Ingelheim$1K
  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $8K from 38 others

What the payments were for

  • Food & beverage$11,78799%
  • Education$1171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$464,222 in reported general payments places this provider in the 95th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$1,345,050
Medicare patients
1,594
Services billed
7,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban628$844,630
EntrestoSacubitril/Valsartan220$306,415
JardianceEmpagliflozin112$145,501
XareltoRivaroxaban107$145,412
Repatha SureclickEvolocumab95$117,067
VascepaIcosapent Ethyl46$38,669
BrilintaTicagrelor25$28,919
WegovySemaglutide15$20,548
NexlizetBempedoic Acid/Ezetimibe18$20,219
FarxigaDapagliflozin Propanediol18$17,824
Icosapent Ethyl24$10,408
Ranolazine ErRanolazine62$8,776
Rosuvastatin Calcium567$8,097
Metoprolol Succinate662$7,851
Ezetimibe310$6,427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$880$844,630628 claims
NovartisEntresto$262$306,415220 claims
Boehringer IngelheimJardiance$1,298$145,501112 claims
Johnson & JohnsonXarelto$1,224$145,412107 claims
AstraZenecaBrilinta, Farxiga$748$46,74343 claims
Novo NordiskWegovy$246$20,54815 claims
Esperion Therapeutics, Inc.Nexlizet$368$20,21918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Manassas

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →